Find Clinical Trials

Inclusion Criteria: * Have type 2 diabetes * Have HbA1c ≥7.5% to ≤10.5% at screening * Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening * Have had a stable body weight for the three months prior to screening * On stable treatment dose of one of the following incretins for at least three months prior to screening: * Injectable semaglutide (1 and 2 milligram (mg)) * Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg) Exclusion Criteria: * Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma * Have a prior or planned surgical treatment for obesity * Have any of the following cardiovascular conditions within three months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have used insulin to control blood glucose within the past year (short-term use allowed) * Current use of prohibited oral antihyperglycemic medication (OAM) (including but not limited to, Dipeptidyl Peptidase IV Inhibitors (DPP-4i) and meglitinides) may be randomized if the prohibited OAM treatment was discontinued at least 3 months prior to screening * If participant has been on stable doses (for at least three months) of up to three permitted OAMs (limited to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and/or thiazolidinediones (TZD), they are permitted to participate in the study * Have taken any medications or alternative remedies for weight loss within three months prior to screening

Inclusion Criteria: * Controlled Diabetes Mellitus type 2 with HbA1c \<7.5% * BMI 23-35 kg/m2 * On anti-cholesterol therapy Exclusion Criteria: * Using injection therapy (insulin or GLP-1 RA) * History of bees product allergy * Active smoker * Consuming alcohol * Altered liver (ALT\>35 IU/L) and kidney (eGFR\<90 mL/min) function * Pregnant and breastfeeding women * History of cardiovascular disease (heart attack, stroke)

Inclusion Criteria: 1. Female and male patients with histologically verified and radically treated stage II-III hormone receptor positive HER2-negative breast cancer; 2. Age ≥ 18 at the time of initiation of ribociclib therapy; 3. Patients who were prescribed ribociclib + AI (±GnRH agonist for premenopausal men and women) not earlier than 28 days before signing the informed consent; 4. It is allowed to start adjuvant hormone therapy with AI (±GnRH agonist) not earlier than 12 months before the start of ribociclib; 5. Provision of written informed consent. Exclusion Criteria: 1. Patients participating in any interventional clinical study at the time of signing the informed consent; 2. Patients receiving active treatment for malignant neoplasms other than BC at the time of enrollment.

Inclusion Criteria: * Age 18 years and older (inclusive) * Female * Preoperative pathology confirmed invasive breast carcinoma or ductal carcinoma in situ * Scheduled for sentinel lymph node biopsy * Capable of and willing to provide informed consent Exclusion Criteria: * Patients with a confirmed allergy to methylene blue or sodium citrate tracers * Pregnant or lactating women * Patients unwilling to participate in the clinical study

Inclusion Criteria: * female * aged 18-74 years * self-identifying as Black and/or Latina * no personal history of breast cancer * English- or Spanish-speaking * having received a mammogram with normal results in the last 12 months * ≥20% lifetime breast cancer risk per the NCI Breast Cancer Risk Assessment Tool (BCRAT) Exclusion Criteria: * aged \<18 or ≥75 * pregnancy

Inclusion Criteria: * difficult-to-treat asthma . * Patients aged 18 years or older Exclusion Criteria: * Patients or volunteers unable to undergo type 1 and type 3 sleep studies, * Patients with symptoms compatible with other sleep disorders, * Patients with a history of or current stroke or transient ischemic attack and Other chronic respiratory diseases. * Patients diagnosed with obstructive sleep apnea

Inclusion Criteria: 1. be a Veteran currently receiving PRRC, MHICM and/or BHIP services at VA San Diego, Los Angeles, or Albuquerque (e.g., seen in the clinic in the past month or based on clinic criteria) 2. meet SAMHSA criteria of serious mental illness; i.e., "having (within the past year) a diagnosable mental, behavior, or emotional disorder that causes serious functional impairment that substantially interferes with or limits one or more major life activities," based on chart review and clinician consultation if needed 3. Be age 18 or above 4. Be fluent and literate in English. 5. Agree to have a subset of VA mental health treatment appointments audiotaped Exclusion Criteria: 1. primary substance use or organic neurological disorder diagnosis determined by chart review 2. are determined by clinician and/or study staff to be at significant risk of exacerbation of symptoms, suicidal ideation, or other risk due to study participation 3. have a history and/or current risk of violence that clinicians and/or study staff determine to be too high risk to manage effectively in the study setting (e.g., poses a risk to Veterans or study staff).

Inclusion Criteria: * Diagnosed with T2DM by a physician * Being between the ages of 19-65 * Having a body mass index (BMI) between 20-35 kg/m2 * Using oral anti-diabetics and not using insulin Exclusion Criteria: * History of gastrointestinal diseases * High consumption of nuts, flaxseeds or sesame seeds (more than one serving per day) * Food allergies or intolerances * Malignancies * Renal failure, liver, other endocrine or inflammatory disorders * Use of lipid-lowering drugs * Smoking and alcohol use * Being pregnant or lactating

Inclusion Criteria: * Participants in this study will be restricted to living kidney transplant donors (LKDs). . Exclusion Criteria: * Those who do not meet Mayo Clinic Rochester's clinical criterion for donor nephrectomy. * \>10% weight change between the donor evaluation and donor nephrectomy * Individuals who are pregnant or are planning to become pregnant * Inability to comply with study procedures or any condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.

Inclusion Criteria: * 18 years or older * ECOG or WHO performance status 0 or 1 * Diagnosis of resectable iCCA on imaging. No histological confirmation is needed before surgery, according to standard of care. * Patient is able to undergo a laparotomy. * Positioning of a catheter for HAIP chemotherapy is technically feasible based on a CT-scan with early arterial phase with 1mm cuts. The default site for the catheter insertion is the GDA. Accessory or aberrant hepatic arteries are no contraindication for catheter placement. * Adequate bone marrow, liver, and renal function before inclusion (values may be max. 30 days old) * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^ 9/L * White blood cell count (WBC) ≥ 2.5 x 10\^9/L * Platelets ≥ 100 x 10\^9/L * Glomerular filtration rate (GFR) ≥ 30 ml/min * Haemoglobin (Hb) ≥ 5.5 mmol/L * Total bilirubin ≤ 25 µmol/L * Written informed consent must be given according to ICH/good clinical practice (GCP), and national/local regulations. Exclusion Criteria: * Presence of extrahepatic disease at the time of first presentation. Patients with locoregional lymph node disease or with small (≤ 1 cm) extrahepatic lesions that are too small to characterize or biopsy are eligible. * Second primary malignancy, except for adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence or with a life expectancy longer than 5 years. * Known homozygous dihydropyrimidine dehydrogenase (DPYD) deficiency * Prior hepatic radiation, ablation, or resection for iCCA. * Clinical evidence of portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis). Some postoperative ascites is allowed. * (Partial) portal vein thrombosis in future liver remnant. * Pregnant or lactating women. * History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for HAIP chemotherapy. * Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator. * Organ allografts requiring immunosuppressive therapy. * Serious infections (uncontrolled or requiring treatment). * Participation in another interventional study for iCCA with survival as outcome. * Participation in another prospective study with an interventional medical product. * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Inclusion Criteria: * 1a. Patients enrolled in the PSCV with a diagnosis of type 2 diabetes mellitus and who, in turn, have a glycated hemoglobin ≥ 7% (during the last 6 months). * 1b. Patients with a diagnosis of periodontitis (≥ 2 non-adjacent teeth with detectable clinical interproximal attachment loss or, attachment loss ≥ 3mm with depth to probing ≥ 3mm on free faces of ≥ 2 teeth, where the attachment loss was not attributed to non-periodontal causes (Papapanou et al., 2018)). Exclusion Criteria: * 2a. Patients who have received periodontal treatment during the last year. * 2b. Pregnancy/lactation, because they are under treatment under the Explicit Health Guarantee "Oral and Integral Health of Pregnant Women". * 2c. Therapy with antibiotics and/or non-steroidal anti-inflammatory drugs (NSAIDs) in the last 6 months prior to the study.

Inclusion Criteria: * Value above a cut-off of the DASS-21 subscales (depression \> 10, anxiety \> 6, and stress \> 10) * Sufficient cognition and language ability (clinical rating) * Sufficient therapy motivation (clinical rating) Exclusion Criteria: * Behavioral disorders (e.g., high irritability or apathy in clinical rating) * Other severe mental disorder (dementia, psychosis, personality disorders, intellectual disability) * Simultaneous psychotherapy or neuropsychological therapy

Key Inclusion Criteria: * Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder. * Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression. * Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study. * Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1). * Willing and able to comply with all study procedures and restrictions in the opinion of the investigator. Key Exclusion Criteria: * A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD. * Are considered by the investigator to be at imminent risk of suicide or injury to self or others. * Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.

Inclusion Criteria: * Female over 18 years of age * Diagnosis of invasive breast cancer (histological proof via breast biopsy) * Tumor size less than or equal to clinical T2 according to the current cTNM classification for breast cancer" * No clinical and/or radiological evidence of lymph node involvement * Affiliation to a French social security scheme or beneficiary of such a scheme * Approval in the multidisciplinary tumor board meeting for conservative treatment with partial mastectomy combined with sentinel lymph node biopsy * Signed informed consent indicating that the patient understands the purpose and procedures required by the study and agrees to participate in the study and comply with its requirements and restrictions Exclusion Criteria: * Severe and morbid obesity (BMI strictly greater than 35) * Emaciation (BMI strictly less than 18.5) * Contraindication to the medications used in the protocol * Contraindication to general anesthesia * Contraindication to the local anesthesia protocol * Tumor considered non-resectable under local anesthesia according to the surgeon's assessment * Bifocal tumor * Associated oncoplastic procedure * Contralateral surgical procedure (implantable port placement, mastopexy, partial or total mastectomy) * Withdrawal of consent prior to surgery * Legal incapacity or limited legal capacity * Non-fluency in the French language or poor understanding as anticipated by the investigator * Subject without health insurance * Pregnant woman * Subject currently in the exclusion period of another study or listed in the national volunteer registry

Inclusion Criteria: * Obesity (BMI and waist circumference using sex and ethnic-specific thresholds for obesity and significant abdominal adiposity) * adults (≥18years) * hypertension (SBP 120-160 mmHg) * on stable antihypertensive, antihyperglycemic, antihyperlipidemic, or anti-obesity medications (≥3-months) * not planning new weight loss for the duration of the trial * 50% living with type 2 diabetes, HbA1c 6.5-9.0% Exclusion Criteria: * Individuals with a history of major cardiovascular events in the last year (stroke or myocardial infarction) * type 1 diabetes diagnosis * recent weight loss or weight gain (≥5% over \<6 months) * current treatment with insulin * eating disorders; substance abuse disorders * serious depression or psychiatric disorders * bariatric or recent surgery (\<6 months) * uncontrolled hypertension (SBP/DBP \>160/100 mmHg) * angina pectoris * gastrointestinal and malabsorption disorders (i.e. inflammatory bowel disease, celiac), pancreatitis, chronic kidney or liver disease, cardiac condition that compromises normal function (e.g. mitral valve disease, heart failure), major disability or disorder requiring continuous medical attention. * herb or supplement use that may affect primary outcome. * alcohol use \>3 drinks/day; participation in another trial. * allergies/intolerances to soy; allergies/intolerances to tree nuts, peanuts and seeds (the combination of all 3). * chronic or prescribed use of certain medications including prescription high dose NSAIDs, antacids, warfarin, medications affecting NO synthesis (i.e. sildenafil, organic nitrates, etc.) * acute or chronic infection (e.g. active HIV, TB, COVID-19, chronic inflammatory infections) * chronic inflammatory condition (such as rheumatoid arthritis) * use of antibiotics within 3-months of the study start

Inclusion Criteria: * Low eHealth literacy (eHeals scale ≤ 29) * No acute or untreated medical problems * Mini Mental State Examination (MMSE) ≥ 24 * Geriatric Depression Scale (GDS) \< 2 Exclusion Criteria: * A myocardial infarction or stroke within 6 months * Painful arthritis, spinal stenosis, amputation, painful foot lesions or neuropathy limiting balance and mobility * Uncontrolled hypertension * Advanced Parkinson's disease or other neuromuscular disorder * Metastatic cancer or immunosuppressive therapy * Significant visual or hearing impairment

Inclusion Criteria * Provision of signed and dated informed consent form * Male or female * Age: birth to 21 years of age * Equipped with a central venous catheter (CVC) for central venous pressure (CVP) monitoring indication as part of standard of care, or undergoing cardiac catheterization. Exclusion Criteria: * Weight less than 2.5kg at the time of enrollment. * Bilateral external jugular veins not accessible due to vascular access or dressing. * Bilateral skin lesion contraindicating neck Ultrasound * Active bleeding * Clinically unstable, per clinical assessment by attending physician and/or surgeon

Inclusion Criteria: 1. Subjects ≥ 55 years 2. Moderate and severe visual impairment (BCVA ≥1/10 and ≤2/10) 3. Diagnosis of advanced non-exudative age-related macular degeneration (AMD) 4. Informed consent freely granted and acquired before the start of the study 5. Ability to understand and willingness to follow the study instructions and procedures Exclusion Criteria: 1. Visual impairment due to other ocular diseases 2. Mild visual impairment or partial or total blindness 3. Exudative age-related macular degeneration undergoing intravitreal drug treatment

Inclusion Criteria: Master Trainers: To be eligible to participate in this study, an individual must meet all the following criteria: 1. Adult women aged 18 years and older 2. Histologically confirmed stage 0-III breast cancer 3. No evidence of metastatic disease 4. Self-identify as Black 5. Able to communicate in English Participants: To be eligible to participate in this study, an individual must meet all the following criteria: 1. Adult women aged 18 years and older 2. Histologically confirmed stage 0-III breast cancer 3. No evidence of metastatic disease 4. Within four-years of diagnosis 5. Self-identify as Black 6. Able to communicate in English Community Interventionists: To be eligible to participate in this study, an individual must meet all the following criteria: 1. Adult women aged 18 years and older 2. Histologically confirmed stage 0-III breast cancer 3. No evidence of metastatic disease 4. Self-identify as Black 5. Former study participants that have completed the intervention 6. Able to communicate in English General Exclusion Criteria: 1. Men or woman below 18 years of age 2. Does not have a histologically confirmed breast cancer 3. There's evidence of metastatic disease 4. Does not self-identify as Black 5. Unable to communicate in English Additional Exclusion Criteria - Participants 1. More than four years of diagnosis Additional Exclusion Criteria - Community Interventionists 1\. Has not previously participated in and completed the study intervention as a participant

Inclusion Criteria: * Female students studying at Istanbul Aydın University, Faculty of Health Sciences, Those who score 111 or above on the Premenstrual Syndrome Scale (PMSS), Female students aged 18-24 will be included in the study. Exclusion Criteria: * Non-Turkish speakers, Individuals who cannot communicate normally, Students who are unable to comply with the exercise program will be excluded from the study.